FDA drafts guidance on using next-generation sequencing to assess gene therapy safety - raps.org
FDA has drafted guidance on using next-generation sequencing (NGS) to assess gene therapy safety, which may affect how sponsors validate and use NGS in their submissions.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 17, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Sponsors of gene therapy products, including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities involved in gene therapy development. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the change text.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The FDA has issued draft guidance on the use of next-generation sequencing for assessing gene therapy safety, which may introduce new expectations for NGS-based assays in regulatory submissions.
Who it affects
Sponsors of gene therapy products, including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities involved in gene therapy development.
What you must do
Review the draft guidance to understand potential new expectations for NGS use in gene therapy safety assessment, and consider providing comments to the FDA.
Deadline
Not specified in the change text.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Guidance: Determining Whether to Submit an ANDA or a 505(b)(2) Application
- FDA proposes rule to ease registration for distributed manufacturers, require foreign API sites to register - raps.org
- FDA Allowing Florida to Import Cheaper Drugs from Canada - supplychainbrain.com
- FDA proposes rule to streamline drug manufacturing registration By Investing.com - Investing.com Canada
- Not Joking Around: FDA Offers Additional Clarification on Compounded GLP-1 Policy in April Fool’s Day Announcement - natlawreview.com